Competition and Markets Authority

Business

Nvidia's Earnings Loom: Does Timing Your Buy Before Feb. 25 Matter? Historical Data Suggests Patience

As Nvidia prepares to report its fiscal Q4 earnings on February 25th, investors are weighing whether to buy ahead of the event. While the AI chip leader's long-term story remains compelling, a look at its recent post-earnings stock performance reveals a pattern that favors a measured approach over trying to time the market.

Feb 2, 2026

US

Search Intensifies for Missing Mother of NBC's Savannah Guthrie in Arizona

Authorities in Pima County are conducting an extensive search for Nancy Guthrie, 84, the mother of 'Today' show co-host Savannah Guthrie, who was reported missing from her Tucson-area home under circumstances described as 'very concerning.'

Feb 2, 2026

Business

Coeur Mining Clears Key Hurdle in $7 Billion New Gold Takeover, Aims for 2026 Completion

A British Columbia court has given its final approval to Coeur Mining's planned acquisition of New Gold, moving the deal that will create a North American precious metals giant one step closer to its expected H1 2026 closing.

Feb 2, 2026

Business

Buell's $10M Federal Lifeline: A Crucial Test for the Reborn American Motorcycle Maker

A new federal loan aims to help the revived Buell Motorcycle Company scale production of its high-performance Super Cruiser, testing whether niche innovation can find a sustainable path in a competitive market.

Feb 2, 2026

Business

Eli Lilly Bets Nearly $2 Billion on Repertoire Immune Medicines to Pioneer Next-Generation Autoimmune Therapies

Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.

Feb 2, 2026

Business

Zegna's Direct-to-Consumer Pivot Fuels Growth, Offsets Wholesale Retreat in 2025

The Ermenegildo Zegna Group reported a 1.1% organic revenue increase to €1.91 billion for 2025, powered by robust DTC performance. While annual sales dipped slightly on a reported basis, a strong fourth-quarter acceleration signals the payoff of its strategic channel shift.

Feb 2, 2026

Business

Billion-Pound Ambition Meets Market Reality: Xeinadin Sale Shelved as Bidders Balk at Price

Private equity firm Exponent has halted the auction of UK accounting group Xeinadin after potential buyers refused to meet its £1bn valuation, signaling potential headwinds for deal-making in the professional services sector.

Feb 2, 2026

World

UK Military on High Alert as Drone Incidents Near Bases Double in a Year

Newly released figures reveal a sharp 111% increase in unauthorized drone activity near UK defence sites in 2025, prompting an expansion of military powers to counter the aerial threat.

Feb 2, 2026

World

Iran Detains Four Foreign Nationals Amid Post-Protest Crackdown

Iranian authorities announced the arrest of four foreigners allegedly involved in last month's widespread unrest, seizing homemade explosives in the operation as the government continues to blame external actors for domestic turmoil.

Feb 2, 2026

Business

Analysts Reassess RenaissanceRe: Price Target Reset Signals Shifting Risk Perceptions

A recent revision to RenaissanceRe Holdings' official price target has refocused market attention on the reinsurer, highlighting how evolving analyst assumptions—rather than a specific number—are reshaping the investment narrative around the stock.

Feb 2, 2026

World

Philippine VP Sara Duterte Hit with Fresh Impeachment Complaints Over Corruption Allegations

Vice President Sara Duterte faces renewed impeachment efforts in the Philippine Congress, centered on allegations of misusing millions in confidential funds. The move reignites political tensions in a nation grappling with the legacies of powerful political dynasties.

Feb 2, 2026

Business

InflaRx's Cash Runway Narrows: Can the Biotech Steer Through Financial Headwinds?

With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.

Feb 2, 2026

Business

The $15,000 Lesson: How Cutting One Major Expense in 2016 Could Have Reshaped Your Finances

A look back at 2016's recurring bills reveals a stark financial truth: small, consistent savings on expenses like cable, cell plans, or insurance, when invested, could have yielded a significant nest egg by today.

Feb 2, 2026

Business

Phillips 66's Turnaround Gains Momentum as Capital Efficiency Improves

The refiner's journey from losses to profitability, marked by a rising Return on Capital Employed (ROCE), is drawing investor attention. While its 5.1% ROCE still lags the industry, the positive trajectory suggests strategic reinvestment is paying off.

Feb 2, 2026

Business

TJX Companies Sees Surging Profitability as Capital Efficiency Hits New Highs

The off-price retail giant TJX Companies is demonstrating remarkable capital efficiency, with its return on capital employed (ROCE) soaring to 31%—far outpacing industry averages—even without significant increases in capital investment over the past five years.

Feb 2, 2026

Business

HBAR's Path to Recovery: Technical Divergences Offer Hope Amidst Broken Accumulation Streak

Despite a 35% monthly plunge, Hedera's HBAR shows signs of underlying buyer interest through key technical divergences. However, a critical shift in exchange flows threatens to delay any near-term price rebound, leaving the token at a pivotal juncture.

Feb 2, 2026

Business

Ripple CTO Pours Cold Water on Lofty XRP Price Predictions Amid Market Downturn

Ripple's Chief Technology Officer, David Schwartz, has expressed skepticism about XRP reaching prices of $50 or $100, triggering a debate within the community as the cryptocurrency's value drops significantly this week.

Feb 2, 2026

Business

EyePoint's Stock Soars 195% in Three Years Despite Persistent Losses, Sparking Investor Debate

While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.

Feb 2, 2026

Business

Citi Trends Stock Soars 77% in a Year, Outpacing Market Amid Turnaround Hopes

While passive index funds mirror the broader market, selecting individual winners can dramatically boost returns. Citi Trends (NASDAQ: CTRN) shares have surged 77% over the past year, far exceeding the market's 14% gain, as investors bet on a potential revival despite ongoing profitability challenges.

Feb 2, 2026

Business

Kinsale Capital Group's Stock Slump: A Buying Opportunity or a Warning Sign After Q3?

Shares of specialty insurer Kinsale Capital have tumbled over 11% in six months, starkly underperforming the surging S&P 500. As investors digest its latest earnings, the debate intensifies: Is this a rare chance to buy a high-growth company at a discount, or a signal of deeper challenges ahead?

Feb 2, 2026